# US 2019/0153049 A1 · Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0153049 A1
- Document ID: US20190153049A1
- Status: Published application
- Kind: A1
- Application number: 15/779,382
- Filed: 2016-10-26
- Published: 2019-05-23
- Earliest claimed: 2015-11-26
- Assignees: Guangzhou Cas Lamvac Biotech Co., Ltd.
- Applicants: Guangzhou Cas Lamvac Biotech Co., Ltd.
- Inventors: Yongchao Yao; Hemei Qi; Wenzhong Guo; Li Qin; Xiaoping Chen
- Web page: https://patentgrep.com/patent/US20190153049A1

## CPC

- C07K 14/445: Plasmodium
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/438: {Hemosporidia antigens, e.g. Plasmodium antigens}
- A61P 35/00: Antineoplastic agents
- C07K 14/70517: {CD8}
- C07K 14/70532: {B7 molecules, e.g. CD80, CD86}
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- C12N 5/0636: {T lymphocytes}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70521: {CD28, CD152}
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides an anti-placenta chondroitin sulfate (pl-CS) chimeric antigen receptor and application thereof. The chimeric antigen receptor mainly comprises anti-pl-CS antigen recognition region, a hinge region, a transmembrane region and intracellular region, wherein the anti-pl-CS antigen recognition region is any one of a plasmodium protein VAR2CSA, a part of peptide segment of plasmodium protein VAR2CSA or a pl-CS antibody; and the part of peptide segment of the plasmodium protein VAR2CSA is a peptide segment with the number of amino acid greater than 500 in the plasmodium protein VAR2CSA.

## Claims

### Claim 1

A chimeric antigen receptor of anti-placental-like chondroitin sulfate, mainly comprising an antigen recognition region of anti-pl-CS, a hinge region, a transmembrane region, and an intracellular region in tandem arrangement;
wherein, the antigen recognition region of anti-pl-CS is any one of Plasmodium falciparum protein VAR2CSA, partial peptide fragment of the Plasmodium falciparum protein VAR2CSA, or antibody against pl-CS; and
the partial peptide fragment of the Plasmodium falciparum protein VAR2CSA is a peptide fragment having a number of amino acids greater than 500 from the Plasmodium falciparum protein VAR2CSA.

### Claim 2 (depends on 1)

The chimeric antigen receptor according to claim 1, wherein the Plasmodium falciparum protein VAR2CSA is a VAR2CSA protein of Plasmodium falciparum strain pf 3D7 and/or a VAR2CSA protein of Plasmodium falciparum strain pf FCR3;

### Claim 3 (depends on 1)

The chimeric antigen receptor according to claim 1, wherein the hinge region is the hinge region of human CD8α.

### Claim 4 (depends on 1)

The chimeric antigen receptor according to claim 1, wherein the transmembrane region is the transmembrane region of human CD28.

### Claim 5 (depends on 1)

The chimeric antigen receptor according to claim 1, wherein the intracellular region is any one of the intracellular region of human CD3ζ, the intracellular region of human CD28, or the intracellular region of human 4-1BB, or a combination of at least two thereof.

### Claim 6 (depends on 1)

The chimeric antigen receptor according to claim 1 wherein the chimeric antigen receptor further contains a human CD8α signal peptide at its amino terminus.

### Claim 7 (depends on 1)

The chimeric antigen receptor according to claim 1, wherein the chimeric antigen receptor is composed of human CD8α signal peptide, VAR2CSA, hinge region of human CD8α, transmembrane region and intracellular region of human CD28, intracellular region of human 4-1BB and intracellular region of human CD3ζ in tandem arrangement.

### Claim 8 (depends on 1)

The chimeric antigen receptor according to claim 1 wherein the chimeric antigen receptor is expressed through transfecting the nucleic acid sequence encoding it into T cells.

### Claim 9 (depends on 1)

A composition comprising the chimeric antigen receptor according to claim 1.

### Claim 10 (depends on 1)

A method for preparing chimeric antigen receptor T cells, comprising expressing the chimeric antigen receptor according to claim 1 in T cells.

### Claim 11 (depends on 1)

A method for treating tumors, comprising administrating the chimeric antigen receptor according to claim 1.

### Claim 12 (depends on 2)

The chimeric antigen receptor according to claim 2, wherein the VAR2CSA protein of Plasmodium falciparum strain pf 3D7 has an amino acid sequence of SEQ ID NO.3, and a nucleic acid sequence of SEQ ID NO.4.

### Claim 13 (depends on 2)

The chimeric antigen receptor according to claim 2, wherein the VAR2CSA protein of Plasmodium falciparum strain pf FCR3 has an amino acid sequence of SEQ ID NO.5, and a nucleic acid sequence of SEQ ID NO.6.

### Claim 14 (depends on 1)

The chimeric antigen receptor according to claim 1, wherein the partial peptide fragment of the Plasmodium falciparum protein VAR2CSA is ID1-ID2a, which has an amino acid sequence of SEQ ID NO.7, and a nucleic acid sequence of SEQ ID NO.8.

### Claim 15 (depends on 3)

The chimeric antigen receptor according to claim 3, wherein the hinge region of human CD8a has an amino acid sequence of SEQ ID NO.9, and a nucleic acid sequence of SEQ ID NO.10.

### Claim 16 (depends on 4)

The chimeric antigen receptor according to claim 4, wherein the transmembrane region of human CD28 has an amino acid sequence of SEQ ID NO.11, and a nucleic acid sequence of SEQ ID NO.12.

### Claim 17 (depends on 5)

The chimeric antigen receptor according to claim 5, wherein the intracellular region is the intracellular region of CD3ζ, the tandem arrangement of the intracellular region of human CD28 and the intracellular region of human CD3ζ, the tandem arrangement of the intracellular region of human 4-1BB and the intracellular region of human CD3ζ, or the tandem arrangement of the intracellular region of human CD28, the intracellular region of human 4-1BB and the intracellular region of human CD3ζ.

### Claim 18 (depends on 17)

The chimeric antigen receptor according to claim 17, wherein the intracellular region of human CD3ζ has an amino acid sequence of SEQ ID NO.13, and a nucleic acid sequence of SEQ ID NO.14.

### Claim 19 (depends on 17)

The chimeric antigen receptor according to claim 17, wherein the tandem arrangement of the intracellular region of human CD28 and the intracellular region of human CD3ζ has an amino acid sequence of SEQ ID NO.15, and a nucleic acid sequence of SEQ ID NO.16.

### Claim 20 (depends on 17)

The chimeric antigen receptor according to claim 17, wherein the tandem arrangement of the intracellular region of human 4-1BB and the intracellular region of human CD3 has an amino acid sequence of SEQ ID NO.17, and a nucleic acid sequence of SEQ ID NO.18.

### Claim 21 (depends on 17)

The chimeric antigen receptor according to claim 17, wherein the tandem arrangement of the intracellular region of human CD28, the intracellular region of human 4-1BB and the intracellular region of human CD3ζ has an amino acid sequence of SEQ ID NO.19, and a nucleic acid sequence of SEQ ID NO.20.

### Claim 22 (depends on 6)

The chimeric antigen receptor according to claim 6, wherein the human CD8α signal peptide has an amino acid sequence of SEQ ID NO.21 and a nucleic acid sequence of SEQ ID NO.22.

### Claim 23 (depends on 7)

The chimeric antigen receptor according to claim 7, wherein the chimeric antigen receptor has an amino acid sequence of SEQ ID NO.1 and a nucleic acid sequence of SEQ ID NO.2.

### Claim 24 (depends on 8)

The chimeric antigen receptor according to claim 8, wherein the transfection is performed by any one of viral vector, eukaryotic expression plasmid, or mRNA sequence, or combination of at least two thereof.

### Claim 25 (depends on 24)

The chimeric antigen receptor according to claim 24, wherein the viral vector is any one of lentiviral vector, adenovirus vector, or retrovirus vector, or a combination of at least two thereof.
